A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab

Abstract The phase 2 KNOCKOUT (NCT05283135) study evaluates higher-than-approved doses of risankizumab, an interleukin-23 inhibitor, for treatment of moderate-to-severe plaque psoriasis. Patients received either 300 or 600 mg of risankizumab at Weeks 0, 4, and 16 and were monitored for 100 weeks wit...

Descripción completa

Detalles Bibliográficos

Autores principales:	Andrew Blauvelt, Rundong Jiang, Linyu Shi, Lam C. Tsoi, Rachael Bogle, Jennifer Fox, Mehrnaz Gharaee-Kermani, Allison C. Billi, Robert T. Matheson, Huzefa Photowala, Johann E. Gudjonsson, Benjamin D. Ehst
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2025-12-01
Colección:	Nature Communications
Acceso en línea:	https://doi.org/10.1038/s41467-025-67475-0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!